The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Mechanistic insights into purinostat mesylate for treating hematologic malignancies
Lijuan Chen, MD, PhD, West China Hospital, Sichuan University, Chengdu, China, shares insights into the mechanisms of purinostat mesylate (PM), an HDAC inhibitor targeting HDAC1 and 2B, and its potential when combined with pomalidomide. Dr Chen highlights that the high selectivity of PM is crucial to avoiding toxicity, and that its mechanism of action is distinct from that of pan-HDAC inhibitors, such as panobinostat, which have been withdrawn from the market due to their severe toxicity. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
